120 One-hundred milligrams of Golimumab showed numerically higher incidences of serious infections, demyelinating events, and lymphoma than 50 mg of Golimubab does
Pipeline drugs like Vikings VK2735 and Amgens AMG 133 could raise the bar further by innovating on both biology and delivery, such as new receptor targeting strategies, novel molecular designs, and more patient-friendly dosing schedules
The rising prevalence of type 2 diabetes and obesity, rising aging populations and lifestyle changes, development of new and improved formulations, such as oral and multi-agonist therapies, and the increasing awareness regarding dual benefits of GLP-1 analogues for glycemic control and weight loss are some of the factors driving the expansion of GLP-1 analogues market
GLP-1 medications slow down gastric emptying
That framing has slowly shifted as the FDA began classifying severe obesity as a chronic disease and as the clinical evidence for GLP-1 receptor agonists in cardiovascular risk reduction accumulated [1]
4-Acetamidophenol (Standard)
